Skip to content
Screener

Syndax Pharmaceuticals SNDX Business Segments — Marketing And Advertising Expense

Similar metrics at other companies

Ponce Financial Group, Inc. logo
PDLBMarketing And Advertising Expense
$190K-28.6%
WSFS Financial logo
WSFSMarketing And Advertising Expense
$2.57M+33.4%
First Internet Bancorp logo
INBKMarketing And Advertising Expense
$706K+0.6%
Wintrust Financial logo
WTFCMarketing And Advertising Expense
$20.43M+8.9%
PNC Financial Services logo
PNCMarketing And Advertising Expense
$110M+11.1%
Origin Bancorp logo
OBKMarketing And Advertising Expense
$1.65M+42.5%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.82B+69.0%
Enterprise value$2.04B+57.0%
P/S8.4×-5.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:MarketingAndAdvertisingExpense.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
March 31, 2026Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Other R&D programs162921
Personnel cost and other expenses19,29816,531
General and administrative expenses
Commercial related expenses7,72110,825
Personnel cost and other expenses16,70119,082
Other SG&A expenses5,1404,412
Stock-based compensation12,05310,380
Royalty interest expense11,8468,049

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's business segments — marketing and advertising expense?
Syndax Pharmaceuticals (SNDX) reported business segments — marketing and advertising expense of $7.72M in Q1 2026.
How has Syndax Pharmaceuticals's business segments — marketing and advertising expense changed year-over-year?
Syndax Pharmaceuticals's business segments — marketing and advertising expense decreased by 28.7% year-over-year, from $10.83M to $7.72M.
What is the long-term trend for Syndax Pharmaceuticals's business segments — marketing and advertising expense?
Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — marketing and advertising expense has grown at a 193.7% compound annual growth rate (CAGR), from $2.12M to $53.63M.
What does business segments — marketing and advertising expense mean?
This represents the expenditures dedicated to promoting and creating market awareness for the company's oncology products. It includes costs for medical education, sales force support, and promotional campaigns aimed at healthcare providers. This metric is critical for evaluating the company's commercialization strategy and the effectiveness of its market entry efforts.

Ask your AI about Syndax Pharmaceuticals's business segments — marketing and advertising expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude